KRAS Recombinant Mouse Monoclonal Antibody [A8E6]
Catalog# HA601060
KRAS Recombinant Mouse Monoclonal Antibody [A8E6]
-
WB
-
IHC-P
-
Human
-
Mouse
-
Rat
-
HA610008
不含抗保成分
-
unconjugated
Overview
Product Name
KRAS Recombinant Mouse Monoclonal Antibody [A8E6]
Antibody Type
Recombinant Mouse Monoclonal Antibody
Immunogen
Recombinant protein within human KRAS aa 2-186.
Species Reactivity
Human, Mouse, Rat
Validated Applications
WB, IHC-P
Molecular Weight
Predicted band size: 22 kDa
Positive Control
HEK-293 cell lysate, 22RV1 cell lysate, mouse brain tissue lysate, mouse kidney tissue lysate, rat brain tissue lysate, mouse colon tissue, mouse kidney tissue, rat colon tissue.
Conjugation
unconjugated
Clone Number
A8E6
RRID
Product Features
Form
Liquid
Concentration
Storage Instructions
Shipped at 4℃. Store at +4℃ short term (1-2 weeks). Store at -20℃ long term.
Storage Buffer
PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Isotype
IgG1
Purification Method
Protein A affinity purified.
Application Dilution
-
WB
-
1:500-1:2,000
-
IHC-P
-
1:1,000
Target
Function
The K-Ras protein is a GTPase, a class of enzymes which convert the nucleotide guanosine triphosphate (GTP) into guanosine diphosphate (GDP). In this way the K-Ras protein acts like a switch that is turned on and off by the GTP and GDP molecules. To transmit signals, it must be turned on by attaching (binding) to a molecule of GTP. The K-Ras protein is turned off (inactivated) when it converts the GTP to GDP. When the protein is bound to GDP, it does not relay signals to the cell's nucleus. Several germline KRAS mutations have been found to be associated with Noonan syndrome and cardio-facio-cutaneous syndrome. Somatic KRAS mutations are found at high rates in leukemias, colorectal cancer, pancreatic cancer and lung cancer. KRAS mutations are more commonly observed in cecal cancers than colorectal cancers located in any other places from ascending colon to rectum. KRAS gene can also be amplified in colorectal cancer. Tumors or cell lines harboring this genetic lesion are not responsive to EGFR inhibitors. Although KRAS amplification is an infrequent event in colorectal cancer, it might be responsible for precluding response to anti-EGFR treatment in some patients. Amplification of wild-type Kras has also been observed in ovarian, gastric, uterine, and lung cancers. Driver mutations in KRAS underlie the pathogenesis of up to 20% of human cancers. Hence KRAS is an attractive drug target, however lack of obvious binding sites has hindered pharmaceutical development. One potential drug interaction site is where GTP/GDP binds. However, due to the extraordinarily high affinity of GTP/GDP for this site, it is unlikely that drug-like small molecule inhibitors could compete with GTP/GDP binding. Other than where GTP/GDP binds, there are no obvious high affinity binding sites for small molecules.
Background References
1. Christophe Rosty et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013 Jun;26(6):825-34. doi: 10.1038/modpathol.2012.240. Epub 2013 Jan 25.
2. N Tsuchida, T Ryder, E Ohtsubo. Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. Science. 1982 Sep 3;217(4563):937-9. doi: 10.1126/science.6287573.
Subcellular Location
Cell membrane. Cytoplasm.
Synonyms
c Ki ras2 antibody
c Kirsten ras protein antibody
c-K-ras antibody
c-Ki-ras antibody
Cellular c Ki ras2 proto oncogene antibody
Cellular transforming proto oncogene antibody
CFC2 antibody
cK Ras antibody
GTPase KRas antibody
K RAS p21 protein antibody
ExpandImages
-
Western blot analysis of KRAS on different lysates with Mouse anti-KRAS antibody (HA601060) at 1/2,000 dilution.
Lane 1: HEK-293 cell lysate
Lane 2: 22RV1 cell lysate
Lane 3: Mouse brain tissue lysate
Lane 4: Mouse kidney tissue lysate
Lane 5: Rat brain tissue lysate
Lysates/proteins at 30 µg/Lane.
Predicted band size: 22 kDa
Observed band size: 22 kDa
Exposure time: 43 seconds;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (HA601060) at 1/2,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Anti-Mouse IgG for IP Nano-secondary antibody (NBI02H) at 1/5,000 dilution was used for 1 hour at room temperature. -
Immunohistochemical analysis of paraffin-embedded mouse colon tissue with Mouse anti-KRAS antibody (HA601060) at 1/1,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (HA601060) at 1/1,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue with Mouse anti-KRAS antibody (HA601060) at 1/1,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (HA601060) at 1/1,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded rat colon tissue with Mouse anti-KRAS antibody (HA601060) at 1/1,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (HA601060) at 1/1,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Products with the same target and pathway
KRAS Mouse Monoclonal Antibody [A8E4]
Application: WB,IF-Cell,FC
Reactivity: Human,Mouse,Rat
Conjugate: unconjugated
KRAS Recombinant Mouse Monoclonal Antibody [A8E6] - BSA and Azide free
Application: WB,IHC-P
Reactivity: Human,Mouse,Rat
Conjugate: unconjugated
KRAS Rabbit Polyclonal Antibody
Application: WB,IHC-P
Reactivity: Human,Mouse,Rat
Conjugate: unconjugated
